摘要：Personalized medicine in cancer is based on targeted therapy, often defined as the right drug to the right patient. Decades of research aimed to establish the appropriate targets for each cancer subtype have led to enormous advances in patients' treatment. This is particularly evident in breast cancer (BC) patients, especially HER2+ and HR+ ones, for whom a panel of targeted therapeutic options are today available. These advances, together with implementation of screening/prevention programs, have resulted in significant decline in BC mortality and augmented detection of early lesions. In early BC, when tumor cells are not supposed to have activated their metastatic program yet, the main therapeutic objective resides in restraining local recurrence [1].
